Literature DB >> 15964374

Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation.

D L Stippel1, H U Kasper, K Schleimer, U Töx, C Bangard, A H Hölscher, K T E Beckurts.   

Abstract

This 44-year-old woman developed multifocal hepatocellular carcinoma (HCC) within hepatitis B-induced liver cirrhosis. At the time of listing for transplantation the HCC had progressed beyond the Milan criteria. Due to her young age, high grade of histological differentiation according to biopsy, and lack of therapeutic alternatives, she was listed for transplantation. She received an organ from the Eurotransplant marginal liver list. Immunosuppression was reduced to tacrolimus monotherapy within 4 months. Five months after transplantation bilateral bulky ovarian metastases were seen on computed tomography (CT) scan. A bilateral salphingo-oophorectomy was performed and immunosuppression switched to sirolimus monotherapy. Fourteen months after this procedure and 19 months after transplantation, the patient is asymptomatic with stable liver function. She is free of recurrence as judged by CT scan, bone scan, and alpha-fetoprotein. In conclusion, radical surgical treatment and immunosuppression using sirolimus may achieve tumor-free survival in selected patients with advanced or recurrent HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964374     DOI: 10.1016/j.transproceed.2005.03.013

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence.

Authors:  Marco Vivarelli; Andrea Risaliti
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

Review 2.  Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.

Authors:  Nicola de'Angelis; Filippo Landi; Maria Clotilde Carra; Daniel Azoulay
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

3.  Expression of FK506 binding protein 65 (FKBP65) is decreased in epithelial ovarian cancer cells compared to benign tumor cells and to ovarian epithelium.

Authors:  Rudi Henriksen; Flemming Brandt Sørensen; Torben Falck Ørntoft; Karin Birkenkamp-Demtroder
Journal:  Tumour Biol       Date:  2011-03-12

4.  Liver Transplantation for HCC: A Review.

Authors:  Rahul Kakodkar; A S Soin
Journal:  Indian J Surg       Date:  2011-12-27       Impact factor: 0.656

Review 5.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Authors:  Henning Schulze-Bergkamen; Binje Fleischer; Marcus Schuchmann; Achim Weber; Arndt Weinmann; Peter H Krammer; Peter R Galle
Journal:  BMC Cancer       Date:  2006-10-02       Impact factor: 4.430

7.  RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.

Authors:  Hung Huynh; K H Pierce Chow; Khee Chee Soo; Han Chong Toh; Su Pin Choo; Kian Fong Foo; Donald Poon; Van Chanh Ngo; Evelyn Tran
Journal:  J Cell Mol Med       Date:  2008-05-07       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.